See more : The Hash Corporation (REZNF) Income Statement Analysis – Financial Results
Complete financial analysis of Captor Therapeutics Spolka Akcyjna (CTX.WA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Captor Therapeutics Spolka Akcyjna, a leading company in the Biotechnology industry within the Healthcare sector.
- Bystronic AG (0QW1.L) Income Statement Analysis – Financial Results
- Reunion Neuroscience Inc. (REUN) Income Statement Analysis – Financial Results
- Willamette Valley Vineyards, Inc. (WVVI) Income Statement Analysis – Financial Results
- Silver Castle Holdings Ltd (SLCL.TA) Income Statement Analysis – Financial Results
- DEEPAK CHEMTEX LIMITED (DEEPAKCHEM.BO) Income Statement Analysis – Financial Results
Captor Therapeutics Spolka Akcyjna (CTX.WA)
About Captor Therapeutics Spolka Akcyjna
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 13.20M | 9.16M | 3.99M | 0.00 | 0.00 | 16.00K | 474.00K |
| Cost of Revenue | 6.30M | 2.09M | 741.00K | 6.60M | 4.46M | 2.59M | 95.00K |
| Gross Profit | 6.90M | 7.07M | 3.25M | -6.60M | -4.46M | -2.57M | 379.00K |
| Gross Profit Ratio | 52.28% | 77.21% | 81.41% | 0.00% | 0.00% | -16,062.50% | 79.96% |
| Research & Development | 64.85M | 44.16M | 23.12M | 23.57M | 19.22M | 10.65M | 2.50M |
| General & Administrative | 16.14M | 19.56M | 19.55M | 4.20M | 2.44M | 1.10M | 279.00K |
| Selling & Marketing | 6.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.18M | 19.56M | 19.55M | 4.20M | 2.44M | 1.10M | 279.00K |
| Other Expenses | -7.11M | -18.28M | -7.71M | -15.56M | -13.80M | -7.61M | -2.26M |
| Operating Expenses | 79.92M | 45.44M | 34.95M | 12.22M | 7.86M | 4.15M | 512.00K |
| Cost & Expenses | 86.22M | 47.52M | 35.69M | 12.22M | 7.86M | 4.15M | 607.00K |
| Interest Income | 3.08M | 3.13M | 400.00K | 393.00K | 2.00K | 4.00K | 0.00 |
| Interest Expense | 323.00K | 321.00K | 400.00K | 393.00K | 430.00K | 266.00K | 46.00K |
| Depreciation & Amortization | 5.44M | 7.09M | 7.36M | 6.60M | 4.46M | 2.59M | 600.00K |
| EBITDA | -64.76M | -28.22M | -24.41M | -5.61M | -3.42M | -1.57M | 466.00K |
| EBITDA Ratio | -490.60% | -310.97% | -622.60% | 0.00% | 0.00% | -9,812.50% | 98.31% |
| Operating Income | -73.02M | -38.36M | -31.71M | -12.22M | -7.86M | -4.13M | -133.00K |
| Operating Income Ratio | -553.11% | -418.91% | -795.48% | 0.00% | 0.00% | -25,812.50% | -28.06% |
| Total Other Income/Expenses | 2.49M | 2.47M | -863.00K | -478.00K | -451.00K | -292.00K | -47.00K |
| Income Before Tax | -70.53M | -35.89M | -32.57M | -12.69M | -8.31M | -4.42M | -180.00K |
| Income Before Tax Ratio | -534.25% | -391.94% | -817.16% | 0.00% | 0.00% | -27,637.50% | -37.97% |
| Income Tax Expense | 57.00K | -2.47M | 400.00K | 393.00K | 430.00K | -26.00K | -1.00K |
| Net Income | -70.58M | -33.42M | -32.97M | -13.09M | -8.74M | -4.42M | -180.00K |
| Net Income Ratio | -534.69% | -364.97% | -827.20% | 0.00% | 0.00% | -27,637.50% | -37.97% |
| EPS | -15.19 | -8.02 | -7.99 | -4.02 | -2.68 | -1.36 | -0.06 |
| EPS Diluted | -15.19 | -8.02 | -7.99 | -4.02 | -2.68 | -1.36 | -0.06 |
| Weighted Avg Shares Out | 4.65M | 4.17M | 4.13M | 3.26M | 3.26M | 3.26M | 3.26M |
| Weighted Avg Shares Out (Dil) | 4.65M | 4.17M | 4.13M | 3.26M | 3.26M | 3.26M | 3.26M |
Source: https://incomestatements.info
Category: Stock Reports